Pictet Asset Management Holding SA Buys 26,119 Shares of BioNTech SE Sponsored ADR $BNTX
by Teresa Graham · The Cerbat GemPictet Asset Management Holding SA lifted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 41.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,838 shares of the company’s stock after acquiring an additional 26,119 shares during the quarter. Pictet Asset Management Holding SA’s holdings in BioNTech were worth $8,457,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently made changes to their positions in BNTX. Financial Consulate Inc. bought a new stake in shares of BioNTech in the third quarter worth approximately $36,000. Huntington National Bank grew its position in BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after buying an additional 380 shares during the period. Tower Research Capital LLC TRC grew its position in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the period. Rakuten Securities Inc. grew its position in BioNTech by 188.1% during the third quarter. Rakuten Securities Inc. now owns 1,043 shares of the company’s stock valued at $103,000 after buying an additional 681 shares during the period. Finally, Hantz Financial Services Inc. grew its position in BioNTech by 100.3% during the third quarter. Hantz Financial Services Inc. now owns 1,146 shares of the company’s stock valued at $113,000 after buying an additional 574 shares during the period. 15.52% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
BNTX has been the subject of several recent research reports. Truist Financial upgraded shares of BioNTech to a “strong-buy” rating in a research report on Wednesday, March 25th. BMO Capital Markets cut their target price on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. Leerink Partners lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a research report on Monday, February 2nd. The Goldman Sachs Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th. Finally, Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.13.
Check Out Our Latest Stock Analysis on BNTX
Insider Buying and Selling at BioNTech
In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the transaction, the chief operating officer directly owned 399,387 shares in the company, valued at $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by insiders.
BioNTech Stock Performance
BNTX opened at $97.54 on Friday. The firm has a market cap of $24.67 billion, a P/E ratio of -18.61 and a beta of 1.36. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a 50 day simple moving average of $97.52 and a two-hundred day simple moving average of $101.13. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49.
BioNTech (NASDAQ:BNTX – Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The firm had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%. Equities analysts forecast that BioNTech SE Sponsored ADR will post -4.55 earnings per share for the current fiscal year.
BioNTech Profile
BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.
BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.